News & Videos - OXFORD BIOMEDICA ORD 50P

Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK – 18 September 2024: OXB (LSE:OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the launch of its new corporate brand. Oxford Biomedica is rebranding as OXB, unveiling a more modern and recognisable visual identity that reinforces its transformation into a global pure-play cell and gene therapy CDMO. The new identity reflects OXB’s unique...

Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OXB" or “the Company”), a quality and innovation-led cell and gene therapy CDMO, announces that Lucinda (Lucy) Crabtree Ph.D. has today joined Oxford Biomedica as Chief Financial Officer (CFO) and board member. Lucinda’s appointment was previously announced on 17 July 2024. Lucinda Crabtree was previously at MorphoSys AG where...

Oxford Biomedica to host a free webinar showcasing its AAV expertise Oxford, UK - 27 August 2024: On Wednesday 11 September 2024, Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, will host a free 60-minute webinar on its adeno-associated virus (AAV) development expertise and showcase their recent breakthroughs. The webinar titled “Advanced AAV Processing and Potency through Characterisation of Capsid and Payload Heterogeneity” will feature presentations by: Sarah...

Half Year Trading Update and Notice of Interim Results Full year 2024 revenue and medium-term financial guidance reiterated; underpinned by OXB’s growing market share in the expanding cell and gene therapy market Contracted value of client orders in the first seven months of the year reflective of strong demand for CDMO services at approximately £80 million Revenue backlog stood at approximately £113 million at 31 July 2024; high level of GMP suite reservation for 2025 gives increased...

Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30% Projected FY2024 revenue range of £126 million to £134 million, reflecting the successful integration of ABL Europe and anticipated growth from new and existing client programmes FY2023 revenues and EBITDA expected to be in line with guidance provided at the Interim Results FY2023 Preliminary Results to be...

Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UK Expands Oxford Biomedica’s ability to serve more clients, unlocking development capacity and increasing revenues 3.2 per cent of the Company’s share capital issued to Institut Mérieux at a share price of 407.4p Oxford, UK – 29 January 2024: Oxford Biomedica plc (LSE:OXB)...

Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, will host a free 60-minute webinar offering an in-depth view of the customer journey from client onboarding to the successful manufacture of adeno-associated virus and lentiviral vectors.. This event will demonstrate how unique and transferable technical...

Business Update Current contracted value signed in 2023 of £124 million, an increase of 47% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing) On track to achieve 2023 guidance provided at the Interim Results and reiteration of medium term guidance; growth supported by new orders recently signed across lentivirus, adeno-associated virus (AAV) and adenoviral vectors Progress towards multi-vector multi-site model with transfer of lentiviral...

Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO Oxford Biomedica announces the signing of a sale and purchase agreement with Institut Mérieux for the acquisition of ABL Europe The transaction Provides Oxford Biomedica with multi viral vector CDMO capabilities – to be made available across the Company’s six manufacturing sites in EU, US and UK Expands Oxford Biomedica’s capacity in process and analytical...

Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform PR Newswire EMERYVILLE, Calif., Sept. 20, 2023 The non-exclusive, multi-year license and supply agreement enables use of LentiVector ® with any Kyverna product Agreement supports Kyverna's scalability and reliability of CAR T cell manufacturing goals EMERYVILLE, Calif. , Sept. 20, 2023 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a clinical-stage cell therapy company with the mission of...

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect...

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023 Newly...

Oxford Biomedica to host webinar s howcas ing the TetraVect a TM system Oxford, UK – 0 7 September 202 3 : Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces that it will host a webinar on the TetraVecta TM system, the Company’s 4 th generation lentiviral vector delivery system, on Monday 2 October 2023. The webinar titled “ 4th Generation Lentiviral Vectors: An Improved Gene Delivery System ” will...

Sapio's No-Code ELN to Provide Enhanced Collaboration, Unified Data Access, and Flexible Workflows to viral vector CDMO Oxford Biomedica BALTIMORE, MD / ACCESSWIRE / July 18, 2023 / Oxford Biomedica (OXB), a quality and innovation-led viral vector CDMO, has implemented Sapio's Electronic Laboratory Notebook (ELN) as part of its digital transformation. The integration of Sapio's ELN is set to increase efficiency of completing tasks, and bolster the insight gained from the state-of-the-art...

Sapio's No-Code ELN to Provide Enhanced Collaboration, Unified Data Access, and Flexible Workflows to viral vector CDMO Oxford Biomedica BALTIMORE, MD / ACCESSWIRE / July 18, 2023 / Oxford Biomedica (OXB), a quality and innovation-led viral vector CDMO, has implemented Sapio's Electronic Laboratory Notebook (ELN) as part of its digital transformation. The integration of Sapio's ELN is set to increase efficiency of completing tasks, and bolster the insight gained from the state-of-the-art...

Oxford Biomedica launches TetraVecta TM - the next generation lentiviral vector system Oxford, UK – 1 5 May 202 3 : Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the launch of its 4 th generation lentiviral vector delivery system, TetraVecta TM . This state-of-the-art technology developed at Oxford Biomedica elevates the quality, potency and packaging capacity of lentiviral vectors, while...

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director Oxford, UK – 2 6 th April 202 3 : Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director. Ms Patterson shall join the Board on 1 st May 2023. Ms Patterson has more than 20 years of public company biotech experience including in the cell and gene therapy industry...

Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023 Dr Mathias brings a wealth of experience in innovation, contract development and manufacturing to Oxford Biomedica Stuart Henderson to take on newly created position of Vice Chair and Dame Kay Davies to become Senior Independent Director Oxford, UK – 20 February 202 3 : Oxford, UK – Oxford Biomedica (LSE:OXB), a leading gene and cell therapy group, today announces that Dr Frank Mathias will officially join Oxford Biomedica...

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer Oxford, UK –...

Oxford Biomedica to complete s ale and leaseback of Windrush Court facility for £60 million Oxford, UK – 14 November 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces exchange of contracts for the sale of its Windrush Court facility (the "Property") to Kadans Science Partner (“Kadans”) for £60 million. Completion is due to occur on or around the 18 th November 2022. The sale proceeds of £60 million...